Stock listing
KRX:068270 Celltrion, Inc. (셀트리온) 주가
Follow Celltrion, Inc. into a list and get an email when it puts out news.
Share price · KRX:068270
₩213,000 KRW +5,500 (+2.7%)
Close on Nov 20, 2026
- Day range
- ₩211,000 – ₩216,500 KRWNov 20, 2026
- Volume
- 574,739 sharesNov 20, 2026
- Market cap
- ₩48.57T KRWAt the close on Nov 20, 2026 · price × 228.0M shares outstanding
- 52-week range
- ₩158,500 – ₩239,048 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩94.56B KRWMedian day 413,204 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:068270 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩213,000 | +5,500 | +2.7% | ₩211,000 | ₩216,500 | ₩211,000 | 574,739 | |
| ₩207,500 | -5,500 | -2.6% | ₩210,000 | ₩213,000 | ₩206,500 | 426,338 | |
| ₩213,000 | -1,500 | -0.7% | ₩214,000 | ₩216,500 | ₩211,000 | 338,119 | |
| ₩214,500 | +500 | +0.2% | ₩216,000 | ₩219,000 | ₩212,500 | 348,030 | |
| ₩214,000 | +4,500 | +2.1% | ₩208,500 | ₩215,000 | ₩207,000 | 432,574 | |
| ₩209,500 | +2,500 | +1.2% | ₩208,500 | ₩213,000 | ₩205,000 | 556,344 | |
| ₩207,000 | +4,000 | +2.0% | ₩205,500 | ₩216,000 | ₩205,000 | 734,809 | |
| ₩203,000 | -7,000 | -3.3% | ₩211,000 | ₩213,000 | ₩202,000 | 858,527 | |
| ₩210,000 | -1,000 | -0.5% | ₩211,500 | ₩215,000 | ₩209,000 | 607,425 | |
| ₩211,000 | -4,000 | -1.9% | ₩205,000 | ₩214,500 | ₩203,500 | 1,011,409 | |
| ₩215,000 | +15,000 | +7.5% | ₩207,500 | ₩216,000 | ₩206,000 | 1,974,398 | |
| ₩200,000 | +10,100 | +5.3% | ₩190,700 | ₩201,000 | ₩187,500 | 1,071,844 | |
| ₩189,900 | -2,100 | -1.1% | ₩191,600 | ₩194,000 | ₩189,500 | 305,133 | |
| ₩192,000 | +400 | +0.2% | ₩190,100 | ₩195,400 | ₩189,200 | 326,249 | |
| ₩191,600 | +2,300 | +1.2% | ₩191,200 | ₩193,500 | ₩188,200 | 514,543 | |
| ₩189,300 | -500 | -0.3% | ₩190,300 | ₩192,800 | ₩187,700 | 360,903 | |
| ₩189,800 | +1,200 | +0.6% | ₩189,600 | ₩194,200 | ₩189,200 | 418,176 | |
| ₩188,600 | -1,400 | -0.7% | ₩190,400 | ₩193,300 | ₩188,400 | 418,008 | |
| ₩190,000 | -4,400 | -2.3% | ₩192,900 | ₩196,900 | ₩188,000 | 418,790 | |
| ₩194,400 | +100 | +0.1% | ₩192,900 | ₩195,300 | ₩190,400 | 445,127 | |
| ₩194,300 | -3,300 | -1.7% | ₩195,700 | ₩198,400 | ₩191,200 | 507,504 | |
| ₩197,600 | +200 | +0.1% | ₩200,000 | ₩203,500 | ₩196,800 | 593,982 | |
| ₩197,400 | -800 | -0.4% | ₩195,600 | ₩202,000 | ₩195,100 | 693,751 | |
| ₩198,200 | +4,200 | +2.2% | ₩193,900 | ₩198,400 | ₩189,500 | 647,662 | |
| ₩194,000 | +11,900 | +6.5% | ₩184,500 | ₩195,500 | ₩183,800 | 1,099,634 | |
| ₩182,100 | +2,300 | +1.3% | ₩178,700 | ₩183,500 | ₩175,200 | 839,518 | |
| ₩179,800 | +100 | +0.1% | ₩179,900 | ₩185,000 | ₩178,300 | 466,550 | |
| ₩179,700 | -700 | -0.4% | ₩175,700 | ₩179,800 | ₩173,700 | 477,972 | |
| ₩180,400 | +800 | +0.4% | ₩182,000 | ₩184,400 | ₩179,800 | 386,216 | |
| ₩179,600 | -3,900 | -2.1% | ₩182,000 | ₩182,300 | ₩179,500 | 461,849 | |
| ₩183,500 | +1,100 | +0.6% | ₩182,800 | ₩184,000 | ₩181,200 | 254,258 | |
| ₩182,400 | -200 | -0.1% | ₩185,200 | ₩186,800 | ₩181,100 | 346,310 | |
| ₩182,600 | -1,000 | -0.5% | ₩183,000 | ₩183,750 | ₩180,600 | 319,980 | |
| ₩183,600 | +5,900 | +3.3% | ₩179,100 | ₩184,200 | ₩178,200 | 422,088 | |
| ₩177,700 | -1,200 | -0.7% | ₩179,800 | ₩179,900 | ₩177,700 | 352,051 | |
| ₩178,900 | +600 | +0.3% | ₩178,400 | ₩179,300 | ₩175,500 | 298,374 | |
| ₩178,300 | +900 | +0.5% | ₩178,400 | ₩180,700 | ₩177,600 | 267,873 | |
| ₩177,400 | -1,100 | -0.6% | ₩179,000 | ₩179,700 | ₩176,800 | 294,934 | |
| ₩178,500 | -2,900 | -1.6% | ₩181,800 | ₩182,200 | ₩178,100 | 337,067 | |
| ₩181,400 | +2,000 | +1.1% | ₩179,500 | ₩181,900 | ₩178,200 | 272,063 | |
| ₩179,400 | -900 | -0.5% | ₩182,000 | ₩182,800 | ₩179,400 | 718,200 | |
| ₩180,300 | +3,100 | +1.7% | ₩179,000 | ₩182,400 | ₩177,400 | 328,926 | |
| ₩177,200 | -300 | -0.2% | ₩178,800 | ₩178,800 | ₩176,200 | 259,646 | |
| ₩177,500 | -1,300 | -0.7% | ₩177,700 | ₩180,300 | ₩177,300 | 195,823 | |
| ₩178,800 | +600 | +0.3% | ₩176,500 | ₩180,400 | ₩174,600 | 396,196 | |
| ₩178,200 | -2,600 | -1.4% | ₩177,900 | ₩179,700 | ₩176,500 | 564,770 | |
| ₩180,800 | -2,300 | -1.3% | ₩181,800 | ₩183,500 | ₩180,100 | 742,053 | |
| ₩183,100 | 0 | 0.0% | ₩182,600 | ₩184,200 | ₩181,500 | 372,393 | |
| ₩183,100 | -3,200 | -1.7% | ₩187,500 | ₩188,800 | ₩182,900 | 482,451 | |
| ₩186,300 | -1,800 | -1.0% | ₩188,900 | ₩190,000 | ₩185,100 | 408,399 | |
| ₩188,100 | +1,000 | +0.5% | ₩189,000 | ₩189,100 | ₩186,600 | 270,580 | |
| ₩187,100 | +800 | +0.4% | ₩187,500 | ₩191,100 | ₩184,700 | 406,507 | |
| ₩186,300 | -1,700 | -0.9% | ₩185,200 | ₩189,800 | ₩184,200 | 299,403 | |
| ₩188,000 | -900 | -0.5% | ₩188,000 | ₩190,500 | ₩187,300 | 268,440 | |
| ₩188,900 | -1,800 | -0.9% | ₩188,000 | ₩191,300 | ₩185,000 | 643,636 | |
| ₩190,700 | -600 | -0.3% | ₩190,700 | ₩190,700 | ₩187,600 | 375,920 | |
| ₩191,300 | -2,100 | -1.1% | ₩194,000 | ₩195,400 | ₩190,600 | 255,697 | |
| ₩193,400 | +3,800 | +2.0% | ₩191,300 | ₩195,500 | ₩190,800 | 326,386 | |
| ₩189,600 | -4,400 | -2.3% | ₩193,600 | ₩194,600 | ₩188,900 | 358,412 | |
| ₩194,000 | +1,700 | +0.9% | ₩194,700 | ₩196,800 | ₩192,200 | 314,860 | |
| ₩192,300 | -1,800 | -0.9% | ₩192,100 | ₩193,100 | ₩187,600 | 354,956 | |
| ₩194,100 | 0 | 0.0% | ₩199,100 | ₩202,000 | ₩194,000 | 484,272 |
Splits
11 splits since 2012 · KRX:068270 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 21-for-20 | Split | |
| 21-for-20 | Split | |
| 26-for-25 | Split | |
| 21-for-20 | Split | |
| 51-for-50 | Split | |
| 51-for-50 | Split | |
| 103-for-100 | Split | |
| 103-for-100 | Split | |
| 1-for-2 | Consolidation | |
| 23-for-20 | Split | |
| 3-for-2 | Split |
- Ticker
- KRX:068270
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- KRX
- Currency
- KRW
What changed lately
Latest news
Celltrion Reports Q2 2026 Revenue of KRW 1.3937Tn and Operating Profit of KRW 451.8Bn; Record Quarterly Revenue as New Product Growth and Cost Improvements Boost Profitability
Jul 26, 2026
Closed ₩178,700 (+0.6%) on Jul 27, 2026
Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)
Apr 21, 2026
Closed ₩194,286 (+0.5%) on Apr 22, 2026
Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
Mar 16, 2026
Closed ₩196,190 (+3.0%) on Mar 17, 2026
Zymfentra (Celltrion) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Mar 13, 2026
Closed ₩190,476 (-2.7%) on Mar 16, 2026
Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference
Jan 13, 2026
Closed ₩201,429 (-4.3%) on Jan 14, 2026
Celltrion to present at the 44th Annual J.P. Morgan Healthcare Conference
Jan 6, 2026
Closed ₩200,952 (-0.9%) on Jan 7, 2026
Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
Dec 1, 2025
Closed ₩176,952 (+0.1%) on Dec 1, 2025
Celltrion, Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 8 in the last 12 months · 27 in all · newest Jul 27, 2026 · oldest 2021
Valuation
P/E 30.8× against a median of 37.5×: 5th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩47.70T KRW
- P/E
- 30.8×
- EV/sales
- 9.7×
- EV/EBITDA
- 25.9×
- Price/book
- 2.7×
- Gross margin
- 61.9%
- Operating margin
- 31.7%
- Net margin
- 32.2%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Celltrion, Inc. · KRX:068270 | US$36.30B | US$35.65B | 30.8× | 9.7× | 25.9× | 2.7× | 32.2% | 0.0× | n/a |
| Roche Holding Ltd · SIX:RO | US$51.16B | US$77.45B | 3.3× | 1.1× | 2.9× | 1.3× | 20.9% | 1.0× | n/a |
| Sun Pharmaceutical Industries Limited · NSE:SUNPHARMA | US$48.80B | US$45.53B | 41.2× | 6.8× | 24.4× | 5.1× | 17.8% | 0.0× | n/a |
| Teva Pharmaceutical Industries Limited · TASE:TEVA | US$46.34B | US$46.29B | 89.8× | 3.3× | 13.5× | 5.8× | 3.7% | 0.5× | n/a |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A · SSE:600276 | US$44.90B | US$38.38B | 33.8× | 7.8× | n/a | 4.5× | 27.0% | 0.0× | n/a |
| Sandoz Group Ltd · SIX:SDZ | US$41.49B | US$46.45B | 43.3× | 4.2× | 23.6× | 4.6× | 8.6% | 0.7× | n/a |
| Zoetis Inc. · NYSE:ZTS | US$32.69B | US$40.21B | 13.0× | 4.2× | 10.2× | 9.9× | 26.4% | 2.7× | 0.69 |
| Divi's Laboratories Limited · NSE:DIVISLAB | US$32.03B | US$32.03B | 101× | 26.4× | 74.8× | 17.7× | 26.1% | 0.0× | n/a |
| Hansoh Pharmaceutical Group Company Limited · HKEX:3692 | US$23.77B | US$18.81B | 28.6× | 8.4× | 21.6× | 4.2× | 37.0% | 0.1× | n/a |
| United Therapeutics Corporation · NASDAQ:UTHR | US$23.63B | US$21.56B | 19.2× | 6.8× | 15.2× | 3.8× | 38.6% | 0.0× | 0.46 |
| Incyte Corporation · NASDAQ:INCY | US$23.36B | US$20.09B | 57.9× | 3.3× | n/a | 4.1× | 6.7% | 0.0× | 0.48 |
| Median of the others | US$37.09B | US$39.29B | 37.5× | 5.5× | 18.4× | 4.5× | 23.5% | 0.1× | 0.48 |
Forecasts
Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.
- Price target
- 279000.00 KRW · Analysts' mean
- EPS, year to Dec 2026
- 5889.39 · 20 analysts
- Revenue, year to Dec 2026
- 5.77T · 19 analysts
Team and board
| Director | Role |
|---|---|
| Seo Jung-jin | Chairman |
Events
- Next results
- Feb 4, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 16, 2026 · Before open | +0.2% |
| Q2 2026 | Aug 6, 2026 · Before open | +2.5% |
| Q1 2026 | May 7, 2026 · Before open | +4.0% |
| Q4 2025 | Mar 3, 2026 · Before open | −5.7% |
| Q3 2025 | Nov 14, 2025 · Before open | +0.5% |
| Q2 2025 | Aug 14, 2025 · Before open | −0.6% |
| Q1 2025 | May 15, 2025 · Before open | −0.5% |
| Q4 2024 | Feb 25, 2025 · Before open | −2.2% |
| Q3 2024 | Nov 14, 2024 · Before open | +0.7% |
| Q2 2024 | Aug 14, 2024 · Before open | +1.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 16, 2024 · Before open | +1.1% |
| Q4 2023 | Feb 29, 2024 · After close | −2.0% |
| Q3 2023 | Nov 14, 2023 · Before open | +1.5% |
| Q2 2023 | Aug 14, 2023 · Before open | −1.6% |
| Q1 2023 | May 12, 2023 · Before open | −1.2% |
| Q4 2022 | Mar 3, 2023 · Before open | +4.8% |
| Q3 2022 | Nov 14, 2022 · Before open | −3.6% |
| Q2 2022 | Aug 16, 2022 · Before open | +1.4% |
| Q1 2022 | May 16, 2022 · Before open | −2.8% |
| Q4 2021 | Feb 15, 2022 · After close | +2.9% |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.16T | 3.56T | 2.18T | 2.28T | 1.91T | 1.85T | 1.13T | 982.1B | 949.1B | 670.6B |
| Cost of revenue | 1.70T | 1.88T | 1.12T | 1.25T | 805.8B | 821.5B | 495.0B | 431.2B | 251.2B | 274.0B |
| Gross profit | 2.47T | 1.68T | 1.05T | 1.03T | 1.11T | 1.03T | 633.5B | 550.9B | 697.8B | 396.6B |
| Research and development | 210.7B | 199.7B | 161.1B | 139.7B | 125.8B | 171.4B | 113.6B | 108.1B | 79.7B | 65.4B |
| Selling, general and administrative | 554.6B | 456.9B | 107.9B | 60.5B | 50.5B | 24.6B | 19.3B | 16.8B | 25.2B | 11.7B |
| Operating income | 1.16T | 492.0B | 651.5B | 647.2B | 756.9B | 718.6B | 381.5B | 323.1B | 499.6B | 249.7B |
| Depreciation and amortization | 287.5B | 418.2B | 245.8B | 226.4B | 214.2B | 173.8B | 153.7B | 124.8B | 98.0B | 88.7B |
| EBITDA | 1.44T | 910.3B | 897.3B | 873.6B | 971.0B | 892.4B | 535.3B | 448.0B | 597.5B | 338.4B |
| Interest expense | 75.5B | 75.6B | 9.67B | 7.51B | 8.24B | 7.50B | 10.8B | 14.7B | 14.7B | 14.1B |
| Income before tax | 1.15T | 576.1B | 671.1B | 626.2B | 751.3B | 657.2B | 382.0B | 301.6B | 483.1B | 229.3B |
| Income tax | 94.8B | 155.5B | 131.4B | 80.6B | 64.2B | 105.3B | 48.9B | |||
| Net income | 1.03T | 422.7B | 535.6B | 537.8B | 579.5B | 517.8B | 301.0B | 245.8B | 368.2B | 178.0B |
| Earnings per share, basic | 4,706.26 | 1,964.25 | 2,583.65 | 3,888.37 | 3,981.73 | 3,559.58 | 2,073.91 | 1,685.57 | 2,536.16 | 1,228.69 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.12T | 996.4B | 564.6B | 551.2B | 1.19T | 684.3B | 546.1B | 410.5B | 419.2B | 268.4B |
| Short-term investments | 119.9B | 146.6B | 192.9B | 43.3B | 31.6B | 14.0B | 81.7B | 121.6B | 138.7B | 5.77B |
| Receivables | 1.79T | 1.22T | 939.2B | 1.72T | 1.28T | 1.44T | 855.0B | 973.4B | 859.6B | 790.3B |
| Inventory | 2.80T | 2.77T | 3.04T | 616.4B | 578.1B | 384.3B | 306.7B | 162.9B | 199.5B | 184.8B |
| Current assets | 6.21T | 5.58T | 5.01T | 2.93T | 3.07T | 2.52T | 1.79T | 1.66T | 1.61T | 1.25T |
| Property, plant and equipment | 950.4B | 946.3B | 923.6B | 881.4B | 844.2B | 867.9B | ||||
| Goodwill | 11.9T | 11.9T | 11.5T | 35.2B | 33.0B | 62.9B | 3.03B | 3.03B | 3.03B | 3.50B |
| Total assets | 22.3T | 21.1T | 19.9T | 5.89T | 5.67T | 5.02T | 3.86T | 3.50T | 3.29T | 3.02T |
| Accounts payable | 124.6B | 75.3B | 50.9B | 50.3B | 80.7B | 34.0B | 42.7B | 20.7B | 21.0B | 21.2B |
| Current liabilities | 4.45T | 3.19T | 2.47T | 1.29T | 1.21T | 1.06T | 657.2B | 678.1B | 616.8B | 610.3B |
| Long-term debt | 387.2B | 86.6B | 99.1B | 151.6B | 170.4B | 199.9B | 139.5B | 103.1B | 224.1B | 208.0B |
| Total debt | 792.3B | 744.4B | 774.4B | 495.4B | 516.6B | 640.9B | 678.9B | |||
| Total liabilities | 4.98T | 3.48T | 2.79T | 1.62T | 1.62T | 1.59T | 986.7B | 907.8B | 883.6B | 823.0B |
| Shareholders' equity | 17.2T | 17.4T | 17.0T | 4.14T | 3.92T | 3.31T | 2.76T | 2.49T | 2.29T | 2.05T |
| Shares outstanding | 218.8M | 215.2M | 207.3M | 138.3M | 145.5M | 145.5M | 145.2M | 145.8M | 145.2M | 144.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 646.1B | 901.9B | 537.2B | 863.5M | 911.2B | 350.7B | 474.0B | 364.8B | 486.0B | 250.9B |
| Capital spending | -331.7B | -333.5B | -353.7B | -312.0B | -321.6B | -541.4B | -286.1B | -187.8B | -97.0B | -178.3B |
| Free cash flow | 314.3B | 568.3B | 183.4B | -311.1B | 589.6B | -190.6B | 187.9B | 177.0B | 389.0B | 72.6B |
| Cash from investing | -355.8B | -472.0B | -251.4B | -175.8B | -245.1B | -162.5B | ||||
| Cash from financing | -350.2B | -69.3B | 266.0B | -85.9B | -198.1B | -96.3B | 28.7B | |||
| Dividends paid | -153.8B | -103.6B | -51.7B | -102.5B | -3.78M | -3.78M | -3.78M | -3.78M | ||
| Share buybacks | -908.4B | -438.8B | -918.8B | -280.5B | -39.1B | -15.9B | -58.2B | -69.0B | -48.7B | -3.62B |
| Change in cash | 122.8B | 431.8B | 13.4B | -637.1B | 504.0B | 138.2B | 135.6B | -8.66B | 150.8B | 118.5B |
Cap table
Built by 6ix from Celltrion, Inc.’s releases · as of Jun 30, 2026
- Common shares
- 228,021,722
- Fully diluted
- 228,021,722
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 228,021,722 | Jun 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 228,021,722 |
| Jun 30, 2026 | 229,327,192 |
Log in to ask 6ix AI your own questions about Celltrion, Inc.